Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria.
Abiu SempereBelén ViñadoIbai Los ArcosDavid CampanyNieves LarrosaNuria Fernandez-HidalgoDolors Rodríguez-PardoJuan José González-LópezXavier NuvialsBenito AlmiranteLaura Escolà-VergéPublished in: Antimicrobial agents and chemotherapy (2022)
This is a retrospective single-center study of 24 patients who received ceftazidime-avibactam plus aztreonam (CZA/ATM) for the treatment of VIM-type-producing Gram-negative bacillus (GNB) infections. The bacteria isolated were Enterobacterales in 22 patients and Pseudomonas aeruginosa in 2. Sixteen out of 19 isolates showed synergistic activity. Two patients presented clinical failure at day 14, and the 30-day mortality was 17% (4/24). CZA/ATM could be considered an alternative therapy for VIM-type-producing GNB infections.
Keyphrases
- gram negative
- end stage renal disease
- multidrug resistant
- pseudomonas aeruginosa
- ejection fraction
- chronic kidney disease
- newly diagnosed
- dna damage
- prognostic factors
- type diabetes
- cardiovascular disease
- escherichia coli
- dna repair
- klebsiella pneumoniae
- risk factors
- oxidative stress
- combination therapy
- acinetobacter baumannii
- smoking cessation